Monitor Incyte's pipeline updates for reallocation of resources from the cancelled study to other programs. The decision removes a potential catalyst in ovarian cancer but avoids a costly late-stage trial with uncertain outcomes.
Drug in focus
INCY drug pipeline →INCB123667
◆ Mixed Named in this 8-K- Impact
- Phase
- Phase 3
- Time to market
- Likely 2029 or later, based on the estimated primary completion date of May 2029 for the MAESTRA 2 pivotal trial, assuming positive results and a subsequent regulatory filing.
- Next catalyst
- None dated
What to watchNo hard binary catalyst (pivotal readout or FDA decision) is expected for INCB123667 within the next 12 months. The MAESTRA 2 Phase 3 trial started December 2025 with estimated completion in 2029. Investors should watch for interim data updates at medical conferences like ASCO 2027 (June) or ESMO 2027 (October), and for enrollment progress updates in Incyte quarterly earnings calls. Near-term value drivers for INCY stock are more likely to come from approved products (Jakafi, Opzelura) and nearer-term pipeline readouts for other assets like povorcitinib and INCA033989.
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Incyte announced it will not proceed with the planned Phase 3 MAESTRA-3 study of its CDK2 inhibitor INCB123667 in ovarian cancer, citing portfolio prioritization rather than safety or efficacy concerns. The company stated the decision will not affect its financial guidance or long-term outlook.
Key Facts
- Incyte decided not to proceed with the planned Phase 3 MAESTRA-3 study evaluating INCB123667, a selective CDK2 inhibitor, in combination with bevacizumab as first-line maintenance therapy in ovarian cancer.
- The study had been expected to begin in Q4 2026.
- The decision was based on prioritization of the clinical development portfolio, not on any safety or efficacy findings from the INCB123667 clinical program.
- Incyte stated the determination is not expected to affect its financial guidance or previously disclosed long-term outlook.
Financial Impact
No financial impact disclosed; company explicitly stated no effect on financial guidance or long-term outlook.
Risk Factors
- Cancellation may signal a narrower pipeline for CDK2 inhibitors, reducing future revenue optionality.
- No safety or efficacy issues were cited, but the portfolio prioritization rationale leaves uncertainty about the drug's future development path.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000879169-26-000068 |
| Document: 0000879169-26-000068-index-headers.html | 0000879169-26-000068 |
| Document: 0000879169-26-000068-index.html | 0000879169-26-000068 |
| Document: 0000879169-26-000068.txt | 0000879169-26-000068 |
Track record
18 reports on INCY
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +23.70% at T+60 after the Jun 8, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $118.50 Now $120.27 +1.49% settles Feb 16
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $123.09 Now $120.27 −2.29% settles Feb 12
- Nov 13, 20263d ago 8-K Neutral 3/10 Viewing Entry $119.45 Now $120.27 +0.69% settles Feb 12
- Nov 12, 20264d ago SC 13G/A Neutral 2/10 Entry $120.97 Now $120.27 −0.58% settles Feb 11
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $122.27 Now $120.27 −1.64% settles Feb 9
- Nov 6, 202610d ago 144 Neutral 4/10 Entry $121.89 Now $120.27 −1.33% settles Feb 5
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $122.85 Now $120.27 −2.10% settles Feb 2
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $116.80 Now $120.27 +2.97% settles Jan 27
- Oct 23, 202624d ago Institutional Cluster Bullish 4/10 Entry $115.71 Now $120.27 +3.94% settles Jan 21
- Aug 14, 202613w ago Insider Cluster Bearish 4/10 Entry $123.50 to $120.30 Now $120.27 +2.62% ▲ +2.59% −0.35% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers